Ryabov S I, Shostka G D, Vinogradova T V
Int Urol Nephrol. 1980;12(2):161-7. doi: 10.1007/BF02089356.
Forty-six patients marked renal failure and anemia underwent androgen therapy (up to 500 mg/week), as well as intravenous injections of iron preparations (600-800 mg/month) and hemotransfusions (2500 ml/month) for 4 month. Ferrokinetic indices, total marrow cellularity and erythrocyte and hemoglobin levels were determined at the end of therapy. Androgens were responsible for the increase in Hb level by 1.2 g%. High total bone marrow cellularity was observed in these patients (27.4 +/- 3.2 X 10(9) cells/kg, compared with 14.1 +/- 1.4 X 10(9) cells/kg in normal individuals). Hemotransfusions resulted in a decrease of Hb level by 1.3g% and total bone marrow cellularity to 8.3 +/- 2.2 X 10(9) cells/kg. Ferrokinetic indices became poor. The data obtained are discussed.
46例伴有明显肾衰竭和贫血的患者接受了雄激素治疗(每周剂量高达500毫克),以及静脉注射铁制剂(每月600 - 800毫克)和输血(每月2500毫升),持续4个月。在治疗结束时测定了铁动力学指标、骨髓总细胞数以及红细胞和血红蛋白水平。雄激素使血红蛋白水平升高了1.2克%。这些患者观察到骨髓总细胞数较高(27.4±3.2×10⁹细胞/千克,而正常个体为14.1±1.4×10⁹细胞/千克)。输血导致血红蛋白水平降低了1.3克%,骨髓总细胞数降至8.3±2.2×10⁹细胞/千克。铁动力学指标变差。对所获得的数据进行了讨论。